$WHG

Susan Byrne Sells 660 Shares of Westwood Holdings Group (NYSE:WHG) Stock

Susan Byrne, a director at Westwood Holdings Group (NYSE:WHG), sold 660 shares of the company's stock on April 28 at an average price of $16.97. This transaction, totaling approximately $11,200, was conducted under a pre-arranged Rule 10b5-1 trading plan, reducing her ownership by 0.23% to 292,616 shares. The company recently paid a quarterly dividend of $0.15, and analysts like Weiss Ratings maintain a "Buy" rating on the stock.

Original reporting
MarketBeat · MarketBeat
Published Apr 30, 2026, 12:09 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Apr 30, 2026, 7:00 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Susan Byrne Sells 660 Shares of Westwood Holdings Group (NYSE:WHG) Stock — source image
Decision brief

The 30-second read

$WHGNeutralLow
01

Why it matters

The transaction's small size and pre-arranged nature suggest limited impact on investor perception. The company's recent dividend and positive analyst outlook support a stable view of the stock.

02

Market read

Insider sales are one of many factors investors consider; in this case, the event is minor and unlikely to influence overall market perception.

03

What to watch

Potential upcoming company developments or earnings reports could influence stock movement more significantly.

Relevance 6/10Timing: short-term

Background

Susan Byrne, a director at Westwood Holdings Group, sold 660 shares on April 28 at an average price of $16.97, totaling approximately $11,200. The sale was conducted under a pre-arranged Rule 10b5-1 plan, indicating a planned transaction rather than reactive selling.

Company-level read

Ticker impact

$WHGNeutralMedium confidence
Context

Recent insider stock sale by a director at Westwood Holdings Group.

Expected impact

Minimal immediate impact on stock price; potential slight downward pressure if viewed as a negative signal, but unlikely to be significant.

Evidence & confidence

Insider sales under a pre-arranged plan are often routine and do not necessarily indicate negative outlooks. The small size of the sale relative to total holdings supports a cautious interpretation.

Market effects

Limited; the sale does not suggest sector-wide concerns.

Negligible; specific to company insider activity.

Minimal; no broader implications.

Counterpoint

The insider sale could be routine diversification or personal liquidity event, not necessarily negative for the company.

Key entities

  • Westwood Holdings Group

    A financial services company specializing in investment management.

Related articles

$WHGMed

Westwood Holdings (WHG) Q2 2026 Earnings Call Transcript

Westwood Holdings Group (WHG) reported Q2 2026 revenues of $25.3 million and net income of $1.5 million, or $0.17 per diluted share. Economic earnings were $3.0 million, or $0.33 per share. Assets under management were $17.0 billion after $1.6 billion net outflows. The firm said its ETF, private capital, and managed solutions segments each exceed $500 million and noted the PWRX ETF will list mid-September on the Texas Stock Exchange.

$WHGMed

Westwood Holdings Group, Inc. Reports Second Quarter 2026 Results

WESTWOOD HOLDINGS GROUP INC (WHG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Westwood Holdings Group, Inc. Reports Second Quarter 2026 Results Private Capital platform surpassed $500 million in assets Managed Investment Solutions flows reached $350 million Dallas, TX, August 6, 2026 – Westwood Holdings Group, Inc. (NYSE: WHG) today reported second quarter

$CMPXMedAI 8/10

Compass Therapeutics publishes tovecimig trial results in JCO

Compass Therapeutics (NASDAQ:CMPX) published Phase 2/3 trial results for tovecimig in the Journal of Clinical Oncology. The study met primary and secondary endpoints, showing improved response rates and progression-free survival in advanced biliary tract cancer patients compared to paclitaxel alone. However, overall survival showed no significant difference, and adverse events were higher in the combination arm. Tovecimig remains investigational.